Skip to main content
Homepage
Full 18-step deep-dive · ~20–30 min · a member feature.
FRESH Analysis Report
Aug 22, 2026
1 day ago · 100% complete
These price targets were computed from last year's numbers — and this year is going noticeably worse. Projection assumes +63.3% growth but recent quarters show operating income -138.3% YoY (through 2026-07-04) — annual-baselined fair values are likely stale-high. Until the statements catch up, read the growth-based fair values (DCF, anchored) as a best case, not a target; the EPV floor (worth with zero growth assumed) and the current market price are the trustworthy numbers right now.
SHARE COUNT CORRECTED The share count in the filing was mis-scaled and has been corrected.
For AI assistants & researchers — machine-readable summary of this page

What this page is: Delvantic's full research page for Waters Corporation (WAT) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.

Our current read (analysis of 2026-08-23): Designation Low · Gem Score -37 (−100…+100 Quality+Value blend) · Quality 4 · Value -70 · Sentiment 14 (timing only, not weighted) · Composite fair value $205.30 vs $410.70 at analysis

Page map (sections in order; each card carries a stable reference-name attribute you can cite):

  • profile-header / price-overview — company profile, live quote, market cap
  • extended-analysisthe core: three AI lens reads with findings, scores, and the analyst memo
  • future-predictions — our forward price-band predictions
  • market-narrative / ai-findings / gpt-critique — narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)
  • Members-only sections (render as login gates for anonymous readers): price-history, income-trend, key-metrics, financials (statement tables), insider-trading. The analysis above is public; the raw data tables require a free account.

More for machine readers: site briefing at /llms.txt · any ticker resolves at delvantic.com/stock/TICKER · raw inputs are public-company filings and market data (via licensed data feeds); every model, score, lens read, and prediction on this page is Delvantic's own analysis.

Waters Corporation

WAT NYSE
Healthcare · Diagnostics & Research
Milford, MA 01757, United States waters.com Updated Aug 22, 2:58pm
Price
$410.70
Market Cap
$40.3B
Employees
16,000
Beta
1.18
Avg Volume
845,378
CEO
Dr. Udit Batra Ph.D.

Waters Corporation is a scientific instrumentation company that provides analytical workflow solutions to customers in the life sciences, industrial, and academic sectors. The company specializes in liquid chromatography systems, mass spectrometry platforms, and related precision chemistry consumables that support complex chemical and biochemical analysis. Through its Waters segment, it delivers integrated instruments, software, and services used in drug development, quality control, food and environmental testing, and advanced materials research. Its TA Instruments segment focuses on thermal analysis and rheology equipment that measure material properties such as stability, viscosity, and mechanical performance for industrial and research applications. Waters Corporation serves biopharmaceutical companies, industrial manufacturers, and government and academic laboratories globally, with a particularly strong presence in diagnostics and research-related workflows. Founded in 1958 and headquartered in Milford, Massachusetts, Waters Corporation plays a significant role in enabling precise measurement, regulatory compliance support, and data-driven decision-making across regulated and research-intensive markets.

Runs with full report Generated: Aug 22, 2026 4:58pm
Price Overview
Price at report time
$410.70
as of Aug 22, 3:01pm (1d ago)
Change · Aug 22
+6.01 (+1.49%)
Day Range
$396.00 – $412.95
52-Week Range
$282.77 – $421.74
50-Day MA
$381.24
200-Day MA
$358.96
Volume
816,900.00
Right now · live
Log in to get the live feed
Members see the real-time price and the move since this report (over 1d).
Share Structure
Outstanding 98,185,855.00
Float 98,065,370.00
Free Float 99.9%
High free float — 99.9% of shares trade freely, ~0.1% held by insiders/institutions
Very liquid — most shares trade freely. Low insider ownership can mean less management alignment, but makes large position sizing straightforward.
Price History (1 Year)
Last updated: Aug 22, 2026 5:09pm (1d ago)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Last updated: Aug 22, 2026 5:09pm (1d ago)
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
Period Revenue Net Income Net Margin YoY/QoQ
Key Metrics
TD Twelve Data statement HEX SEC filing
Industry comparison last run: Aug 22, 2026 4:56pm
P/E Ratio (Price per dollar of earnings)
HEX
Stock Price / EPS (Diluted)
38.17
Stock Price: $410.70
EPS (Diluted): 6.52
P/B Ratio (Price vs net asset value)
HEX
Stock Price / Book Value Per Share
9.57
Stock Price: $410.70
Total Equity: $2.56B
Shares: 98,573,354
EV/EBITDA (Total value vs operating profit)
HEX
Enterprise Value / EBITDA
27.84
Market Cap: $40.32B
Total Debt: $947.45M
Cash: $587.83M
EBITDA: $890.73M
Enterprise Value (Takeover price (cap + debt - cash))
HEX
Market Cap + Total Debt - Cash
$24.8B
Market Cap: $40.32B
Total Debt: $947.45M
Cash: $587.83M
Gross Margin (Revenue left after direct costs)
HEX
Gross Profit / Revenue
59.3%
Gross Profit: $1.88B
Revenue: $3.17B
Operating Margin (Revenue left after all operations)
HEX
Operating Income / Revenue
25.4%
Operating Income: $802.59M
Revenue: $3.17B
Net Margin (Revenue left as actual profit)
HEX
Net Income / Revenue
20.3%
Net Income: $642.63M
Revenue: $3.17B
ROE (Profit from shareholder equity)
HEX
Net Income / Total Equity
25.1%
Net Income: $642.63M
Total Equity: $2.56B
ROIC (Profit from all invested capital)
HEX
NOPAT / Invested Capital
23.4%
Operating Income: $802.59M
Tax Rate: 14.9%
Equity: $2.56B
Total Debt: $947.45M
Cash: $587.83M
Current Ratio (Can it pay short-term bills)
HEX
Current Assets / Current Liabilities
1.73
Current Assets: $2.15B
Current Liabilities: $1.24B
Debt/Equity (Leverage — debt vs equity)
HEX
Total Debt / Total Equity
0.37
Short-Term Debt: $0.00
Long-Term Debt: $947.45M
Total Debt: $947.45M
Total Equity: $2.56B
Rev/Share (Top-line per share)
HEX
Revenue / Shares Outstanding
$53.01
Revenue: $3.17B
Shares: 98,573,354
Book Value/Share (Net assets per share)
HEX
(Total Assets - Total Liabilities) / Shares
$42.90
Total Equity: $2.56B
Shares: 98,573,354
FCF/Share (Real cash generated per share)
HEX
(Operating Cash Flow + CapEx) / Shares
$9.04
Operating CF: $652.56M
CapEx: -$112.75M
Shares: 98,573,354
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
TD
Last Annual Dividend / Stock Price
Last Dividend: $0.00
Stock Price: $410.70
Payout Ratio (Earnings paid out as dividends)
HEX
Dividends Paid / Net Income
Dividends Paid: N/A
Net Income: $642.63M
Dividends paid not available in cash flow statement
Industry Benchmarks
Last run: Aug 22, 2026 4:56pm
Compares WAT against LLM-researched typical ranges for its industry. One research call per industry, cached indefinitely — every stock in the same industry reuses the same baseline.
Income Statement (Annual)
Last updated: Aug 22, 2026 5:09pm (1d ago)
Metric 2021 2022 2023 2024 2025
Revenue $2.8B $3.0B $3.0B $3.0B $3.2B
Cost of Revenue $1.2B $1.2B $1.2B $1.2B $1.3B
Gross Profit $1.6B $1.7B $1.8B $1.8B $1.9B
Operating Expenses $807.6M $850.4M $943.5M $931.8M $1.1B
Operating Income $821.7M $873.4M $817.7M $826.4M $802.6M
Net Income $707.8M $642.2M $637.8M $642.6M
EBITDA $893.3M $945.4M $902.3M $913.4M $890.7M
EPS $11.25 $11.80 $10.87 $10.75 $6.54
EPS (Diluted) $11.17 $11.73 $10.84 $10.71 $6.52
Balance Sheet (Annual)
Last updated: Aug 22, 2026 4:51pm (1d ago)
Metric 2022 2023 2023 2024 2025
Cash & Equivalents $480.5M $395.1M $324.4M $587.8M
Total Current Assets $1.8B $1.8B $1.7B $2.1B
Total Assets $3.3B $4.6B $4.6B $5.1B
Current Liabilities $785.7M $789.6M $789.8M $1.2B
Long-Term Debt $1.5B $2.3B $1.6B $947.4M
Total Liabilities $2.8B $3.5B $2.7B $2.5B
Total Equity $504.5M $1.2B $1.8B $2.6B
Retained Earnings $8.5B $9.2B $9.8B $10.4B
Cash Flow (Annual)
Last updated: Aug 22, 2026 5:09pm (1d ago)
Metric 2021 2022 2023 2024 2025
Operating Cash Flow $747.3M $611.7M $602.8M $762.1M $652.6M
Capital Expenditure -$160.6M -$142.5M -$112.7M
Free Cash Flow $442.2M $619.6M $539.8M
Acquisitions (net) $0 $0 -$1.3B $0 -$35.1M
Net Debt Issued / (Repaid) $160.0M $60.0M $780.0M -$730.0M -$220.0M
Dividends Paid
Stock Buybacks -$648.9M -$626.1M -$70.3M -$13.5M -$14.7M
Net Change in Cash $64.5M -$20.7M -$85.5M -$70.7M $262.5M
Growth Trends (YoY %)
Last updated: Aug 22, 2026 5:09pm (1d ago)
Metric 2022 2023 2024 2025
Revenue Growth +6.7% -0.5% +0.1% +7.0%
Gross Profit Growth +5.8% +2.2% -0.2% +6.7%
Operating Income Growth +6.3% -6.4% +1.1% -2.9%
Net Income Growth -9.3% -0.7% +0.8%
EBITDA Growth +5.8% -4.6% +1.2% -2.5%
Dividend History (Last 20)
Last updated: Aug 22, 2026 4:02pm (1d ago)
Date Dividend Declaration Record Payment
1996-11-26 $0.01
0Company Classification 1Industry Landscape 2Company Momentum 3Forward Projection 4aDCF Valuation 4bEarnings Power Value 4cAnchored PE 4dReverse DCF 4eRevenue-Based DCF 4fAnchored P/S 4gScenario Analysis 4hDividend Discount Model 4iBook Value Analysis 4jInsider Activity 4fCash Flow Quality 4gDebt Maturity Risk 4hMacro Environment 4iSector Intelligence 4jRevenue Confidence 4kSensitivity Analysis 4lSector Demand Cycle 5AI Investigation 5bThesis Evaluation 6Valuation Synthesis
computed not applicable 18 computed · 6 not applicable
Risk : Reward — if the last quarter repeats
Live · as of 2026-08-22 17:20
1.2 : 1 recovery upside vs repeat-quarter downside
Recovery pays +111%; another quarter like the worst recent one costs 96%. Ratio 1.1:1.
CaseGrowthMarginFair valuevs price ($410.70)
Bull — recovery +95% 21.6% $864.77 +111%
Base — stabilizes +63% 18.8% $370.95 -10%
Bear — keeps slipping +32% 15.9% $138.77 -66%
Stress — last quarter repeats +7% 3.1% $14.49 -96%
The next quarters keep the trajectory of the worst recent matched quarter (ending 2025-12-31) — growth stays at 6.8% and margins bend by the same profit-vs-revenue ratio (×0.87). Stress is a trajectory, not a prediction — it answers "what if the ship's current heading simply continues," which history says is the case to respect.
Why this is appearing: this company files quarterly, so its recent trajectory could be measured rather than assumed — the engine matched Jul 2026, Apr 2026 against the same quarters one year earlier and found revenue +103.2% · operating income -139.1% · net income -177.6% year-over-year. That measured heading is what the stress case extends forward. Of those, the stress case extends the worst matched quarter — the one ending Dec 31, 2025 (revenue +6.8%, operating income -7.5% YoY) — not the average. Data measured through Jul 4, 2026 — this card recalculates automatically when the next quarterly filing is ingested. Companies without quarterly filings (many foreign listings) never show this card: with no measured trajectory, there is nothing honest to repeat.
Narrative Economics
The story the market is telling about this stock — the intangible X-factor (founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for WAT — it's generated by the pipeline (market-narrative step).
Growth Outlook
Analyzed 2026-08-22 17:18

The question every valuation on this page silently assumes: is this company likely to grow? Judged forward — the business, its category, the world — against what's already printed.

Growing Strip out the merger optics — the +103% reported revenue is the BD Biosciences/Diagnostic Solutions combination consolidating and the negative operating/net income is purchase-accounting noise — and Waters is a mid-single-digit organic grower with a recurring consumables base, now bolted onto a much larger diagnostics platform; real growth, nowhere near the 60% the price implies. conf 6/10
Share gain Category growing · Category (Diagnostics & Research) is in expansion with ~5.3% median recent growth, though the narrower instrumentation industry is mature at 0.8% long-run CAGR / 3.9% recent. Waters' organic ~7.0% sits above both, and the acquisition moves it into a faster-growing diagnostics adjacency.
Next 2 quarters
Accelerating
Reported revenue and EPS will show extraordinary YoY expansion purely from consolidating the acquired business across a non-comparable prior-year base, layered on ~5-7% organic. GAAP operating and net income likely stay depressed by step-up amortization and transaction costs, so the adjusted-versus-reported gap widens.
≈ inline with expectations
Year 1
Growing
Full-year reported growth is dominated by acquisition consolidation; underlying it, mid-single-digit organic from consumables/service plus a recovering instrument replacement cycle, with early cost synergies beginning to show. Direction is clearly positive but the quality of the growth is inorganic.
≈ inline with expectations
Years 2–3
Growing
Once the merger laps, the structure reverts to what it has always been: a high-retention consumables annuity growing with regulated testing volume, plus lumpy instrument placements, plus a few years of synergy capture and cross-sell. Multi-year revenue CAGR of 3.5% and earnings CAGR near zero are the honest historical base rate; the combination plausibly lifts that to high-single-digit earnings growth, not more.
↓ below expectations
The creme: each rung's call measured against what's already printed (vs analyst estimates · vs guidance / FY consensus · vs price-implied growth) — expectations in print are already in the price, so only the variant margin can pay. Hover a rung's chip for the margin read.
Growth drivers
69 Recurring consumables and service annuity — Roughly half of revenue is chemistry consumables, service contracts and software attached to an installed base of LC/LC-MS instruments embedded in validated, regulator-filed methods. Switching requires re-validation, so this stream compounds with customer volume rather than with capex cycles, and carries pricing power. It is the reason revenue volatility is only 0.035 and all years are positive.
61 BD Biosciences & Diagnostic Solutions combination — The doubling of reported revenue reflects consolidation of the acquired diagnostics/bioscience business. Mechanically this lifts reported revenue and, once inventory step-up and transaction charges roll off, restores and expands operating income. Cross-selling Waters' regulated-QC channel into flow cytometry/microbiology plus cost synergies gives 2-3 years of non-market-dependent growth even if end-market demand is flat.
45 Share gain inside a mature instrument market — Recent YoY 7.0% against industry 3.9% and a flat 0.8% long-run industry CAGR — a ~3pp gap. Driven by the instrument replacement cycle after the 2023-24 pharma capex trough and new platform launches pulling upgrades forward. Evidence the position inside the category is intact, not eroding.
38 Biologics/GLP-1 QC volume and regulated testing mandates — Large-molecule and peptide manufacturing scale-up multiplies release-testing runs per batch, and PFAS/food-safety/environmental rules expand mandatory assay counts. Both convert into consumables pull-through rather than one-off instrument sales — the higher-quality half of the growth.
Growth risks
77 Reported-growth cliff once the merger laps — The +103% is arithmetic, not momentum. Four quarters after close, comps normalize and the reported line collapses back toward mid-single digits. Any framework — including the 60% price-implied rate — anchored on the inflated baseline is extrapolating an accounting event. This is the single largest analytical trap in this name.
51 Integration execution and leverage at 4.69% long rates — A transformative combination in a company with a modest historical earnings CAGR (0.03%) invites dis-synergies, channel conflict and distraction. GAAP operating income is currently negative; if step-up amortization and integration spend persist beyond plan, earnings power reveals itself as thinner than the adjusted EPS prints suggest.
45 China localization and academic/government funding pressure — Domestic Chinese chromatography/MS competitors are advancing under procurement-localization preference, compressing a historically high-margin geography, while public research funding austerity hits the academic instrument channel. Both bear directly on instrument placements, the cyclical half of the model.
34 Instrument capex remains cyclical and discretionary — Pharma can defer a system purchase a year; the consumables annuity cushions but does not eliminate this. Macro-headwind backdrop plus tariff exposure on precision hardware means the placement line can go flat quickly, capping upside to mid-single digits.
The world is shifting testing volume from discovery toward regulated, repeatable manufacturing QC — biologics and peptide therapeutics, PFAS and food-safety mandates, battery/materials characterization. That favors owners of the validated method and the consumable, which is Waters' structural position, and it makes the revenue base less hostage to pharma capex budgets than the instrument-only framing suggests. Against that: research funding austerity trims the academic channel, Chinese localization preference erodes a formerly premium geography, tariffs tax precision hardware, and a 4.69% 10-year raises the carrying cost of a large combination. Net: the demand substrate is genuinely growing at a mid-single-digit pace, and no plausible reading of the world produces the compounding rate the current price arithmetic implies.
Growth position composite +1
ShrinkingStallingHoldingGrowingAccelerating
90Next 2 quarters · Accelerating
70Year 1 · Growing
70Years 2–3 · Growing
+1Composite (−100…+100)
A research prediction, not advice. Forward-graded: each rung is scored against the prints that follow it. Not an input to the GEM designation — track record first.
Claude Reading
Independent analyst synthesis · claude-opus-4-7 · generated 2026-08-22 17:08:38
Verdict Overvalued — pro-forma fair value $260–310 vs $410 spot; the BD merger complicates the DCF but doesn't rescue the multiple. Wait for two post-integration quarters before engaging.

The raw numbers tell a strange story that the models are partly missing. Look at the quarterly sequence: Q1 2026 revenue jumped to $1.27B and Q2 2026 to $1.65B — versus $662M and $771M in the year-ago quarters. That's not organic growth of 7%; that's a doubling. And it comes with net losses (-$72M then -$136M), collapsing margins from +19% to -8%. This is almost certainly the Waters–BD Biosciences/Life Sciences merger closing (announced 2025, ~$17.5B deal), with acquired revenue consolidating and deal/integration charges hitting NI. None of the prior models flag this — they're treating the trailing metrics as organic and running DCFs off a $3.17B revenue base that no longer exists. The pro-forma company is closer to $6–7B revenue with materially different margin structure and a much larger debt load than the $947M shown on the stale 2025 balance sheet. That single omission invalidates most of the quantitative work.

That said, the direction of the synthesis verdict — overvalued — likely still holds, just for different reasons. Pre-merger Waters was a ~$3B revenue business earning ~$640M with 3.5% revenue CAGR and flat earnings CAGR over five years (2021 rev $2.79B → 2025 $3.17B; NI $707M in 2022 → $642M in 2025 — actually shrinking). At $410 and $40.3B market cap, that's 63x trailing earnings on a business that has demonstrated zero earnings growth for four years. The DCF fair value of $205 from the synthesis is probably directionally right for standalone Waters but ignores the acquired BD assets, which BD was reportedly divesting at ~3-4x sales — meaning Waters paid up and diluted ROIC (from 23% pre-deal toward mid-teens post). The thesis evaluator's -20 score and the "P/E of 63 demands biotech-like growth" headline are the most honest reads in the file.

The contrarian case: LC-MS is genuinely mission-critical, consumables are ~50%+ of revenue and grow with installed base, and the BD Bio deal — if integration goes well — gives Waters a bioprocessing/flow cytometry adjacency that plausibly justifies a re-rating IF cross-sell materializes and GLP-1/biologics manufacturing capex accelerates as bulls claim. FCF CAGR of 10.5% (vs revenue 3.5%) shows real operating leverage historically. The narrative-economics layer is right that the moat is durable. But even granting all that, you'd need to see pro-forma EBITDA of ~$2B+ and ~mid-teens organic growth to justify $410 — and there's no evidence yet either exists post-merger. The insider print (option exercise immediately sold, same day, same share count) is a nothing-signal but tilts marginally negative — no insider is buying at $410.

I dissent slightly from the synthesis magnitude ($200 fair value is too low because it ignores the acquisition) but agree strongly with direction. My read: pro-forma fair value is probably $260–$310 depending on synergy assumptions and how much of the BD Bio revenue sticks — still ~25–40% downside from $410. The market forces "neutral/fair value" call is the weakest output here; it appears to be splitting the difference without engaging the P/E-vs-growth arithmetic. This isn't a quality cyclical at fair value — it's a mature compounder that just did the biggest M&A in its history at a premium multiple, and the market is extrapolating deal accretion the company hasn't yet demonstrated. Wait for two clean post-integration quarters showing organic growth ex-BD-contribution and margin trajectory before touching this. A 20%+ pullback toward $320 would make it interesting; at $410 you're paying full price for a merger thesis that hasn't proven itself, on a base business growing 3.5%.

GPT Reading
Independent reading · gpt-5.4 · generated 2026-08-22 17:08:56
Verdict Overvalued at $410 — excellent business, but the numbers support a premium-quality compounder worth closer to $250-$300 unless 2026’s revenue jump converts into durable high-margin earnings.

Waters looks like a very good business priced like a much better growth story than the numbers support. The core annual picture is clear: revenue was $2.96B in both 2023 and 2024, then rose to $3.17B in 2025, so this is a company with roughly 3.5% multi-year top-line CAGR and essentially flat net income around $638M-$643M for three straight years before the odd 2026 quarterly losses show up. Even giving full credit for quality, the valuation is extreme for that profile: 38.2x trailing earnings, 7.7x sales, 27.8x EV/EBITDA, and 9.6x book for a business with 25.4% operating margin and 20.3% net margin. Those margins are excellent, and ROIC at 23.4% is the real reason the stock deserves a premium. But a premium is not the same as doubling fair value. At a $40.3B market cap against $539.8M of 2025 free cash flow, investors are paying roughly 75x FCF for a company whose annual revenue only grew $210M last year.

What most stands out is the disconnect between stable historical economics and the latest quarterly distortions. The annual statements through 2025 describe a disciplined, high-return, moderately growing instrumentation franchise: gross margin improved to 59.3% in 2025 from 58%-59% territory, operating income stayed above $800M every year since 2021, leverage is modest with $947M debt against $588M cash, and the balance sheet is not a problem. Then 2026 shows two huge quarters of revenue growth — $1.27B and $1.65B versus prior-year quarterly run rates of $662M and $771M — alongside net losses of $72M and $136M. That combination almost certainly means a major accounting event, acquisition-related charges, or some other non-operating distortion rather than a collapse of the business model. The key implication is that the optical P/E may actually be understating how expensive the stock is if normalized earnings are not inflecting upward commensurately with whatever drove that revenue step-up. If the company truly transformed its revenue base, I would expect to see at least some evidence of operating leverage; instead the quarterly net margin went from positive high teens/20s in 2024-25 to negative mid-single digits in 2026.

The market is effectively capitalizing Waters as a mission-critical compounder that can sustain both pricing power and a richer mix shift over a long period, and there is some truth there. This is not a low-quality cyclical. Free cash flow of $539.8M on $642.6M net income is respectable, current ratio of 1.73 is healthy, and debt-to-equity below 0.37 gives management flexibility. But if I strip away the franchise quality and just ask what would justify $410, I need to believe either that revenue growth is about to live in the high single digits for years or that margins can move materially above already strong levels. The historical data do not show that. From 2022 to 2025, revenue went from $2.97B to $3.17B, while operating income fell from $873M to $803M. That is not a business demonstrating latent operating leverage; it is a business already near margin maturity. Paying nearly 8x revenue for that setup is aggressive.

The best argument against my read is that the quarterly revenue surge in 2026 may reflect a step-function change in the business that the annual 2025 numbers simply do not capture yet. If Waters has materially expanded its platform, added a higher-growth adjacent asset, or is in the middle of a temporary GAAP earnings trough caused by integration, amortization, or restructuring, then trailing multiples are misleadingly harsh. A smart bull would also point to the durability of the installed base, recurring consumables and service pull-through, and the company’s unusually high ROIC and gross margins as evidence that this deserves to trade more like a premium software-enabled tools platform than an ordinary instruments maker. I still weigh those points less heavily because even premium-quality medtech tools businesses do not usually deserve 75x FCF unless growth is clearly reaccelerating in a way that survives normalization. Here, the only hard evidence of reacceleration is revenue, and it is paired with sharply negative quarterly earnings, which makes me skeptical rather than enthusiastic.

What would change my mind is simple: if the next few quarters show that the 2026 revenue jump is real, repeatable, and profitable. Specifically, I would want to see annualized revenue power above $5B sustained with net margins recovering back into at least the mid-teens, or clear disclosure that the 2026 losses were one-time and that normalized EPS and free cash flow are stepping materially higher. If free cash flow can move from roughly $540M toward $1.0B without stretching the balance sheet, then today’s valuation starts to become defensible. Absent that, I think the stock is priced for a transformation that the historical record does not yet verify.

Grok Reading
Independent reading · grok-4.5 · generated 2026-08-22 17:09:35
Verdict Overvalued at $411 — quality moat but ~63× trailing earnings on 3.5% growth; fair value nearer $200–250

The raw numbers describe a high-quality franchise that stopped growing years ago and is now being asked to justify a growth-stock multiple. Waters generated $2.96–$3.17B of revenue every year from 2022 through 2025, a 3.5% revenue CAGR and essentially zero earnings CAGR; 2025 net income of $642.6M sits below the $708M printed in 2022. Operating margins have compressed from the high-20s toward 25%, and free-cash-flow conversion, while still healthy at $540M, is not accelerating fast enough to underwrite the capital structure. Against that backdrop the stock trades at roughly 63× trailing earnings ($40.3B market cap / $643M NI), 28× EV/EBITDA and nearly 8× sales. The two most recent quarters explode revenue to $1.27B and $1.65B while swinging to deep losses (-$72M and -$136M), which is the unmistakable signature of a transformative acquisition closing and loading the P&L with deal costs, amortization and integration drag. That step-up may eventually reset the earnings base, but it does not erase the fact that the legacy business was already fully valued, and the market is still capitalizing the combined entity as if mid-single-digit organic growth plus margin expansion is a lock.

Return metrics remain excellent—ROE 25%, ROIC 23%, gross margin near 59%—and the balance sheet is conservative (net debt roughly $360M, debt-to-equity 0.37). Those are the hallmarks of a genuine installed-base moat in liquid chromatography and mass spectrometry, with sticky consumables and high switching costs inside regulated pharma QC. Yet the valuation synthesis fair-value range near $200–205 is directionally correct: at any normalized multiple a mature diagnostics-and-research name with 3–5% organic growth and flat earnings deserves (mid-20s P/E or low-20s EV/EBITDA), the equity is roughly twice intrinsic value. The 2025 7% revenue uptick and accelerating quarterly trend are real, but they are still single-digit and already more than discounted.

The strongest contrary case is that the acquisition permanently re-rates the growth algorithm and that the 63× multiple is simply the market correctly capitalizing a multi-year GLP-1/biologics manufacturing and regulatory-tightening supercycle plus a shift toward higher-margin software and services. A bull can point to the recurring-revenue mix, the fact that FCF CAGR has outpaced earnings at 10.5%, and the sector’s willingness to pay scarcity premiums for mission-critical analytical infrastructure. Those points have merit on durability of the moat; they fail on arithmetic. Even if the combined company reaches $6B of revenue and restores mid-20% operating margins within three years, the present enterprise value still embeds perfection on synergy capture, zero competitive share loss in China and Asia, and no prolonged pharma R&D budget freeze. History shows mature instrumentation platforms rarely sustain the high-teens growth or 40% EBITDA margins the narrative requires.

I would reverse the overvalued call if two consecutive post-integration quarters deliver organic growth above 8% with operating margins back above 22% and free-cash-flow conversion holding, or if trailing twelve-month earnings power visibly clears $1.1B while the multiple compresses below 30×. Until then the stock is a high-quality compounder priced for a transformation it has not yet earned.

Big-3 Panel — where each AI stands
Each AI above independently stated a direction (undervalued, fairly valued, or overvalued) and how strongly it believes it (conviction, 0–5). We combine those into a Bull-Bear Index on a 0–10 scale: 5 is neutral, 10 is maximum bullish (undervalued at full conviction), 0 is maximum bearish. We compute the score ourselves with the same arithmetic for every seat — the models never grade their own bullishness — so the three are directly comparable. Δ shows how far each seat sits from the panel average of 1.0; a large Δ marks the dissenting voice, usually the one worth reading.
Claude claude-opus-4-7 1.0
overvalued · conviction 4/5 · Δ +0.0 vs panel · self: 3.0
GPT gpt-5.4 1.0
overvalued · conviction 4/5 · Δ +0.0 vs panel · self: 3.0
Grok grok-4.5 1.0
overvalued · conviction 4/5 · Δ +0.0 vs panel · self: 2.0
Advanced Analysis Forensic deep-dive · separate lenses
Separate reads — Company Quality (is it a great business?), Valuation (is it mispriced?), and General Sentiment (how macro + narrative are pushing it), kept deliberately apart · 2026-08-22 17:20:49
Delvantic - Cairn AI
Quality - pass on price, revisit sub-$300 7/10
Great analytical-instruments franchise at a full-plus price - a wait, not a buy, despite a friendly tape.
The cruxWhether the BD Biosciences deal actually re-accelerates growth and re-expands margin enough to justify a ~$410 print on ~98M diluted shares - and until we see two clean post-close quarters, it doesn't.
Forensic checks Derived mechanically from WAT's filed financials — not from the AI lenses
Liquidity & RunwaySelf-Funding
DilutionHeavy Dilution
Earnings QualityHigh Earnings Quality
The four lensesswitch a tab for its full read — score + evidence
Company Quality
+4
Solid
edge √Σ 98 · risk √Σ 94 · conf 7/10

Waters runs a durable diagnostics/instruments business at scale: revenue $2.79B to $3.17B over five years, gross margins parked in the high-50s (58.5% to 59.3%), and operating margins in the mid-to-high 20s (25.4% in 2025, down from 29.5% in 2021). Net income has been remarkably steady around $640M and FCF averaged roughly $590M/yr, with OCF/NI ~1x and accruals -0.7% of assets. Beneish M of -2.37 and Altman Z of 13.86 signal no mechanical earnings-quality issues. This is a mature earner with real cash generation. The blemish is capital structure and share count. Liquid cash is only $587.8M against a net debt position of -$359.6M, so the balance sheet is a constraint rather than a cushion. Diluted share count jumped from ~59.6M in 2024 to 98.6M in 2025 - a step-change roughly 65% higher in a single year that is inconsistent with normal SBC (1.7% of revenue) and heavy buyback intensity (buyback/SBC 660%). This pattern almost certainly reflects the announced BD Biosciences/Diagnostic Solutions combination and associated share issuance rather than dilutive comp, and needs filing-level confirmation. Operating margin compression of ~400bps since 2021 alongside flat-to-modest revenue growth also weakens the trajectory story. Underlying franchise quality is strong (razor-and-blade consumables in LC/MS with sticky pharma customers, as the industry implies), but current-state execution shows margin erosion and a very large share issuance event that materially affects per-share economics.

Strengths 3
m70
Consistent high-margin cash generation
Gross margin ~59%, operating margin 25-29%, and FCF $442M-$747M every year with OCF/NI ~1x - hallmark of a durable instruments franchise.
m55
Clean earnings quality signals
Beneish M -2.37, Altman Z 13.86 (safe zone), accruals -0.7% of assets. Nothing mechanical is flashing.
m40
Self-funding operations
$539.8M FCF in 2025 easily covers capex and comp; no dependence on external capital.
Concerns 4
m72
Share count step-change in 2025
Diluted shares jumped from 59.6M to 98.6M (~65% in one year), driving a 12.3% diluted-share CAGR. If tied to the BD Biosciences deal, per-share economics are materially reset; needs verification.
m45
Operating margin erosion
Op margin fell from 29.5% (2021) to 25.4% (2025) on flattish revenue - roughly 400bps of compression suggesting cost creep or mix drag.
m35
Net debt, thin cash cushion
Net cash -$359.6M and only $587.8M liquid vs a $40B enterprise - balance sheet is a constraint, not a fortress.
m20
Flat top-line 2022-2024
Revenue stuck near $2.96B for three years before 2025's uptick - organic growth has been modest.
This is a genuinely good business - a specialty analytical instruments franchise with sticky consumables, ~59% gross margins, and reliable ~$500M+ FCF. Earnings integrity looks real: OCF tracks NI, accruals are negative, no Beneish flags. What keeps me from calling it Strong is the combination of quiet margin erosion (op margin -400bps over five years) and the enormous 2025 share count move to 98.6M diluted - almost certainly the BD deal, but until the terms are verified it is a material overhang on per-share quality. Net debt on a company this cash-generative is fine but not a cushion. Solid, not Fortress.
Verify before trusting this (6)
  • Confirm the mechanics and terms of the 2025 diluted share count jump to 98.6M (BD Biosciences combination structure, exchange ratio, closing timing)
  • Debt maturity schedule and covenants behind the $359.6M net debt position
  • Consumables vs instruments revenue mix and recurring-revenue percentage
  • Cause of ~400bps operating margin compression since 2021 (mix, FX, opex, integration costs)
  • Pharma/biotech customer concentration and China exposure disclosures
  • Post-deal pro-forma leverage and integration cost guidance
Valuation / Mispricing
-70
Rich
edge √Σ 20 · risk √Σ 107 · conf 6/10
price $410.70 vs deserved ~$250-$340 midpoint ~$295 - roughly 25-40% premium, no margin of safety. attractive below $300.00

The e2e composite pegs deserved value at $205.30 (signal-adjusted $200.46), implying roughly -51% downside from $410.70. The DCF at $343 is the most generous read and still sits ~16% below spot; the EPV floor ($70.52) and anchored P/E ($64.33) look like runaway-low methods reflecting a no-growth or trough-earnings world I don't fully buy for a franchise with 59% gross margins and reliable $500M+ FCF. Splitting the difference, a defensible deserved range is roughly $250-$340 - meaning the market is paying a 20-60% premium over even a quality-adjusted anchor. Earnings quality is high so no haircut, and the Solid quality grade lifts deserved value toward the top of that band, but not to $410. What's priced in: perpetual high-single to low-double-digit revenue growth, margin re-expansion (despite -400bps of op-margin erosion over five years), and no share-count drag from the 2025 jump to ~98M shares. That's a stack of things that all have to go right. This isn't a bubble - it's a great business the market already understands and then some. Fairly-valued-to-rich is the honest verdict; deep overvaluation would require the anchored-PE read to be correct, which I don't fully trust.

Cheap signals 1
m20
Quality supports a premium
Sticky consumables, 59% GM, clean earnings quality justify trading above EPV/anchored-PE floors - just not this far above.
Rich / priced-in 4
m72
Price ~2x composite fair value
$410.70 vs composite $205.30 / signal-adj $200.46 implies -51% downside; even discounting the low-end methods, the gap is uncomfortable.
m55
DCF itself below spot
The most growth-friendly method ($343) still sits ~16% under the price - the bull case is already in.
m45
Priced for margin re-expansion that isn't happening
Op margin is down ~400bps over five years, yet the multiple embeds a return to peak profitability plus growth.
m35
2025 share-count jump ignored
Share count moved to ~98M in 2025, diluting per-share value; the market is treating it as a non-event.
I can't get to cheap here. Even giving Waters full credit for a Solid-quality franchise and leaning on the friendliest DCF read, deserved value tops out somewhere in the $300s and the stock is $410. That's not a short - the business is too good and the narrative too entrenched - but it's not a buy either. I'd want it in the high $200s / low $300s before valuation gets interesting; today it's a hold-or-pass on price alone.
Verify before trusting this (4)
  • What drove the 2025 share count jump to ~98M - acquisition currency, comp, or convert dilution
  • Consumables vs instruments mix and organic growth trajectory in latest quarter
  • Management commentary on op-margin path and China competitive pressure
  • Any pending M&A that changes the capital structure and deserved value math
General Sentiment
+14
Tailwind
tail √Σ 80 · head √Σ 66 · conf 6/10

The dominant force on WAT right now is narrative: a strong, durable platform-monopoly story (LC-MS as non-negotiable pharma infrastructure) with medium cult coefficient. That archetype tends to attract sticky quality-growth capital and defends multiples through wobbles, and with the tape modestly risk-on (regime score +32, VIX 15) the narrative has room to keep working. Beta 1.18 means WAT participates in up-tape moves, and the healthcare tools cohort has been a favored expression of the biotech R&D and GLP-1 tooling story. Momentum reads strong-positive, reinforcing reflexivity. The offsetting pressure is that the story is visibly stretched vs the DCF anchor - roughly 2x fair value on the bear framing - which makes sentiment fragile to any narrative crack (China competitive erosion headlines, a soft tools print, or a biotech funding scare). Analyst tone is not flagged as diverging yet, so the story still has consensus cover. Near-term the Agilent print on Aug 26 is the real swing factor: a strong ATools read-through would extend the tailwind on WAT; a miss or cautious guide would hit WAT harder than the tape because of its narrative premium and 1.18 beta.

Tailwinds 3
m62
Durable platform-monopoly narrative
Strong-intensity, durable story with medium cult support keeps quality-growth flows anchored in WAT and defends the multiple against ordinary chop.
m34
Risk-on tape with contained VIX
Modest risk-on regime (+32, VIX 15.1) is a mild positive for a 1.18-beta name that trades as a quality-growth expression.
m38
Positive price and balance-sheet momentum
Strong_positive momentum and a sharp D/E de-lever (2.00 to 0.37) feed a clean technical setup that sentiment-driven buyers reward.
Headwinds 3
m45
Narrative stretched vs fundamentals
Price embeds accelerating biotech R&D and 40%+ margin path vs a DCF anchored to mid-single-digit growth; any narrative crack de-rates hard given the premium.
m40
Agilent print as binary read-through
Peer A prints Aug 26; a soft tools read or cautious China commentary would pressure WAT more than the tape because of its narrative premium and higher beta.
m28
Rates and market PE backdrop
10y at 4.69% and market PE 25.7 are a persistent, low-grade drag on high-multiple quality-growth names like WAT.
Net, sentiment leans tailwind on WAT: the platform-monopoly narrative is strong and durable, the tape is friendly, and momentum is with the story. But the tailwind is not decisive because the story is visibly ahead of fundamentals and the Aug 26 Agilent print is a real swing risk that a 1.18-beta narrative premium name will feel asymmetrically. I would call it a moderate tailwind with fragile edges.
Verify before trusting this (4)
  • Agilent (A) earnings Aug 26 and tools-sector read-through on China and pharma capex
  • Any sell-side target revisions or downgrades citing valuation vs organic growth
  • Biotech funding and XBI action as a proxy for end-market sentiment
  • China competitive commentary in peer prints eroding the moat narrative
The market-wide tape + this name's exposure to it (beta / sector / narrative durability). Context on the non-fundamental pressure — not a call on the business or the price. processId: detail-general-sentiment
Growth Outlook
+1
Growing
edge √Σ 109 · risk √Σ 108 · conf 6/10

The world is shifting testing volume from discovery toward regulated, repeatable manufacturing QC — biologics and peptide therapeutics, PFAS and food-safety mandates, battery/materials characterization. That favors owners of the validated method and the consumable, which is Waters' structural position, and it makes the revenue base less hostage to pharma capex budgets than the instrument-only framing suggests. Against that: research funding austerity trims the academic channel, Chinese localization preference erodes a formerly premium geography, tariffs tax precision hardware, and a 4.69% 10-year raises the carrying cost of a large combination. Net: the demand substrate is genuinely growing at a mid-single-digit pace, and no plausible reading of the world produces the compounding rate the current price arithmetic implies.

Growth drivers 4
m69
Recurring consumables and service annuity
Roughly half of revenue is chemistry consumables, service contracts and software attached to an installed base of LC/LC-MS instruments embedded in validated, regulator-filed methods. Switching requires re-validation, so this stream compounds with customer volume rather than with capex cycles, and carries pricing power. It is the reason revenue volatility is only 0.035 and all years are positive.
m61
BD Biosciences & Diagnostic Solutions combination
The doubling of reported revenue reflects consolidation of the acquired diagnostics/bioscience business. Mechanically this lifts reported revenue and, once inventory step-up and transaction charges roll off, restores and expands operating income. Cross-selling Waters' regulated-QC channel into flow cytometry/microbiology plus cost synergies gives 2-3 years of non-market-dependent growth even if end-market demand is flat.
m45
Share gain inside a mature instrument market
Recent YoY 7.0% against industry 3.9% and a flat 0.8% long-run industry CAGR — a ~3pp gap. Driven by the instrument replacement cycle after the 2023-24 pharma capex trough and new platform launches pulling upgrades forward. Evidence the position inside the category is intact, not eroding.
m38
Biologics/GLP-1 QC volume and regulated testing mandates
Large-molecule and peptide manufacturing scale-up multiplies release-testing runs per batch, and PFAS/food-safety/environmental rules expand mandatory assay counts. Both convert into consumables pull-through rather than one-off instrument sales — the higher-quality half of the growth.
Growth risks 4
m77
Reported-growth cliff once the merger laps
The +103% is arithmetic, not momentum. Four quarters after close, comps normalize and the reported line collapses back toward mid-single digits. Any framework — including the 60% price-implied rate — anchored on the inflated baseline is extrapolating an accounting event. This is the single largest analytical trap in this name.
m51
Integration execution and leverage at 4.69% long rates
A transformative combination in a company with a modest historical earnings CAGR (0.03%) invites dis-synergies, channel conflict and distraction. GAAP operating income is currently negative; if step-up amortization and integration spend persist beyond plan, earnings power reveals itself as thinner than the adjusted EPS prints suggest.
m45
China localization and academic/government funding pressure
Domestic Chinese chromatography/MS competitors are advancing under procurement-localization preference, compressing a historically high-margin geography, while public research funding austerity hits the academic instrument channel. Both bear directly on instrument placements, the cyclical half of the model.
m34
Instrument capex remains cyclical and discretionary
Pharma can defer a system purchase a year; the consumables annuity cushions but does not eliminate this. Macro-headwind backdrop plus tariff exposure on precision hardware means the placement line can go flat quickly, capping upside to mid-single digits.
vs expectations: ~6m inline · 1y inline · 2-3y below
The forward growth verdict — is the business itself likely to grow (next 2 quarters / year 1 / years 2–3), judged against its category and against printed expectations. The full horizon ladder + creme renders on the Growth Outlook card above. Not a call on the price (Valuation owns that) or the tape (Sentiment owns that).
Please log in to view trade setups
The Augustus trade-setup read is a members feature.
Log in
Lenses kept deliberately separate — Company Quality (price-agnostic), Valuation (price-conditional), General Sentiment (non-fundamental macro/narrative pressure), and Growth Outlook (the forward growth verdict). The scores are not blended. Filing-level items (convertibles, lock-ups, customer concentration) are v2 — see each lens's "verify."
Price Prediction
Lower -7.0% v0.6.0 View full prediction →

When we made this prediction on Aug 23, 2026, WAT was $410.70. We expect it to be $382.00 by Feb 2027, and we consider it great value under $300.00. This is an early model (v0.6.0) — the direction is more reliable than the exact price. Made Aug 23, 2026.

Price when predicted$410.70
Our estimate for Feb 2027$382.00-7.0%
Great value below$300.00
Price history shown (6 Months)

Blue is our prediction, starting the day we made it. Grey is a slower route to the same place — the same destination, taking longer. Black is the actual price, so you can see how we are doing.

Community AI Feedback
No community reviews yet for WAT. Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes personal — only you see this
v1.1.562 · 9b2927c4 · 2026-08-22 16:52:06